SEC Tracker
Get the app

BridgeBio Pharma BBIO

KKR Genetic Disorder (Affiliate) plans to sell 5,800,000 BBIO shares, about $156.3M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Sep 13, 2024
  2. Broker: J.P. Morgan Securities LLC
  3. Shares acquired by: Conversion of Series B preferred units into shares of common stock (1); Conversion of Series C preferred units into shares of common stock (1); Conversion of Series D preferred units into shares of common stock (1)

All of KKR Genetic Disorder's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when BridgeBio Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  2. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  3. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  4. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  5. Repligen RGEN public float $6.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.